Yükleniyor... / Loading...
This study analyzed the clinical experience with the drug Rucaparib in ovarian cancer patients treated within Spain's Rucaparib Access Program. It included women aged 18 and older with high-grade epithelial ovarian, fallopian tube, or peritoneal cancer treated under this program. This is a study without an assigned phase and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: 1. Written informed consent must be signed by all patients participating in the study who can be interviewed in the hospital (accessible, alive patients). Informed consent may not be required from unaccessible patients (dead, lost, etc.) according to ethics committee permissions and applicable law for retrospective studies in Spain. 2. Histological diagnosis of high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer treated in the context of rucaparib access program (RAP) in Spain. 3. Adult women (18 years or more at the time of diagnosis). Exclusion Criteria: 1\. Patients without medical record available (lost, empty or unretrievable clinical information).